Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) Stock Competitors & Peer Comparison
See AMPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMPH | $21.81 | +0.30% | 955.9M | 7.40 | $2.93 | N/A |
| TAK | $18.18 | -0.87% | 57.7B | 13.03 | $1.39 | +3.47% |
| HLN | $9.96 | +0.86% | 43.5B | 18.40 | $0.54 | +1.26% |
| TEVA | $37.36 | -0.29% | 42.8B | 12.56 | $2.93 | N/A |
| VTRS | $16.21 | -0.22% | 18.8B | 6.40 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.86 | -2.63% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.15 | +0.29% | 10.1B | 19.88 | $0.61 | +0.69% |
| LNTH | $100.15 | -0.33% | 6.5B | 16.85 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AMPH vs TAK Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TAK has a market cap of 57.7B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TAK trades at $18.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TAK's P/E ratio is 13.03. In terms of profitability, AMPH's ROE is +0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AMPH is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TAK's competition here
Haleon plc (NYSE: HLN)
AMPH vs HLN Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, HLN has a market cap of 43.5B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while HLN trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas HLN's P/E ratio is 18.40. In terms of profitability, AMPH's ROE is +0.10%, compared to HLN's ROE of +0.17%. Regarding short-term risk, AMPH is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AMPH vs TEVA Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TEVA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TEVA's P/E ratio is 12.56. In terms of profitability, AMPH's ROE is +0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, AMPH is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
AMPH vs VTRS Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, VTRS has a market cap of 18.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while VTRS trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas VTRS's P/E ratio is 6.40. In terms of profitability, AMPH's ROE is +0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, AMPH is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AMPH vs ITCI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AMPH's ROE is +0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AMPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AMPH vs ELAN Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ELAN trades at $23.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ELAN's P/E ratio is 22.23. In terms of profitability, AMPH's ROE is +0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, AMPH is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
AMPH vs CTLT Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AMPH's ROE is +0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AMPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AMPH vs RDY Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while RDY trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas RDY's P/E ratio is 19.88. In terms of profitability, AMPH's ROE is +0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, AMPH is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AMPH vs LNTH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while LNTH trades at $100.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas LNTH's P/E ratio is 16.85. In terms of profitability, AMPH's ROE is +0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, AMPH is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
AMPH vs AMRX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while AMRX trades at $17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas AMRX's P/E ratio is 19.89. In terms of profitability, AMPH's ROE is +0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, AMPH is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AMPH vs INDV Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, INDV has a market cap of 4.7B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while INDV trades at $37.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas INDV's P/E ratio is 10.35. In terms of profitability, AMPH's ROE is +0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, AMPH is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
AMPH vs SUPN Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SUPN trades at $46.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SUPN's P/E ratio is 15.51. In terms of profitability, AMPH's ROE is +0.10%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, AMPH is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AMPH vs RGC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas RGC's P/E ratio is -383.10. In terms of profitability, AMPH's ROE is +0.10%, compared to RGC's ROE of -2.32%. Regarding short-term risk, AMPH is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AMPH vs BHC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, BHC has a market cap of 2.6B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while BHC trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas BHC's P/E ratio is 1.74. In terms of profitability, AMPH's ROE is +0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, AMPH is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AMPH vs DCPH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AMPH's ROE is +0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AMPH is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AMPH vs HCM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while HCM trades at $12.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas HCM's P/E ratio is 4.71. In terms of profitability, AMPH's ROE is +0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AMPH is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AMPH vs AVDL Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AMPH's ROE is +0.10%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, AMPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
AMPH vs EMBCV Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AMPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EMBCV's competition here
Perrigo Company plc (NYSE: PRGO)
AMPH vs PRGO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PRGO has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PRGO trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PRGO's P/E ratio is 5.48. In terms of profitability, AMPH's ROE is +0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, AMPH is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PRGO's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AMPH vs DVAX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AMPH's ROE is +0.10%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, AMPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AMPH vs ANIP Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ANIP trades at $76.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ANIP's P/E ratio is 9.41. In terms of profitability, AMPH's ROE is +0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, AMPH is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AMPH vs ETON Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ETON trades at $61.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ETON's P/E ratio is -855.86. In terms of profitability, AMPH's ROE is +0.10%, compared to ETON's ROE of +0.40%. Regarding short-term risk, AMPH is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AMPH vs TARO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TARO's P/E ratio is 30.05. In terms of profitability, AMPH's ROE is +0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AMPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AMPH vs HROW Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, HROW has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while HROW trades at $41.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas HROW's P/E ratio is 467.33. In terms of profitability, AMPH's ROE is +0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, AMPH is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HROW's competition here
Alvotech (NASDAQ: ALVO)
AMPH vs ALVO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ALVO trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ALVO's P/E ratio is -12.56. In terms of profitability, AMPH's ROE is +0.10%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, AMPH is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ALVO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AMPH vs PAHC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PAHC trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PAHC's P/E ratio is 12.01. In terms of profitability, AMPH's ROE is +0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, AMPH is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
AMPH vs CRON Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CRON's P/E ratio is 30.58. In terms of profitability, AMPH's ROE is +0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, AMPH is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AMPH vs PCRX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PCRX has a market cap of 937.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PCRX trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PCRX's P/E ratio is 9.17. In terms of profitability, AMPH's ROE is +0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, AMPH is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AMPH vs PETQ Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AMPH's ROE is +0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AMPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AMPH vs COLL Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, COLL has a market cap of 893.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while COLL trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas COLL's P/E ratio is 3.46. In terms of profitability, AMPH's ROE is +0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AMPH is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
AMPH vs EVO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, EVO has a market cap of 696.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while EVO trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas EVO's P/E ratio is -2.77. In terms of profitability, AMPH's ROE is +0.10%, compared to EVO's ROE of -0.27%. Regarding short-term risk, AMPH is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AMPH vs IRWD Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, IRWD has a market cap of 681.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while IRWD trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas IRWD's P/E ratio is 5.31. In terms of profitability, AMPH's ROE is +0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, AMPH is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AMPH vs BDSI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AMPH's ROE is +0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AMPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check BDSI's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AMPH vs AQST Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, AQST has a market cap of 564M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while AQST trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas AQST's P/E ratio is -7.37. In terms of profitability, AMPH's ROE is +0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, AMPH is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
AMPH vs EOLS Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, EOLS has a market cap of 549.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while EOLS trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas EOLS's P/E ratio is -26.44. In terms of profitability, AMPH's ROE is +0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, AMPH is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EOLS's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AMPH vs TLRY Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TLRY has a market cap of 522.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TLRY trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TLRY's P/E ratio is -4.31. In terms of profitability, AMPH's ROE is +0.10%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, AMPH is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
AMPH vs KMDA Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, KMDA has a market cap of 462.7M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while KMDA trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas KMDA's P/E ratio is 21.11. In terms of profitability, AMPH's ROE is +0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, AMPH is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AMPH vs CGC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CGC has a market cap of 443.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CGC trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CGC's P/E ratio is -0.63. In terms of profitability, AMPH's ROE is +0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, AMPH is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AMPH vs TKNO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TKNO has a market cap of 375.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TKNO trades at $7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TKNO's P/E ratio is -22.58. In terms of profitability, AMPH's ROE is +0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AMPH is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TKNO's competition here
Embecta Corp. (NASDAQ: EMBC)
AMPH vs EMBC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, EMBC has a market cap of 324.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while EMBC trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas EMBC's P/E ratio is 2.10. In terms of profitability, AMPH's ROE is +0.10%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, AMPH is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EMBC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AMPH vs ALIM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AMPH's ROE is +0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AMPH is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
AMPH vs LNDC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AMPH's ROE is +0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, AMPH is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LNDC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AMPH vs ORGO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ORGO has a market cap of 236.8M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ORGO trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ORGO's P/E ratio is 61.33. In terms of profitability, AMPH's ROE is +0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, AMPH is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ORGO's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AMPH vs ACB Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ACB has a market cap of 236M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ACB trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ACB's P/E ratio is -7.78. In terms of profitability, AMPH's ROE is +0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, AMPH is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
AMPH vs TYHT Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AMPH's ROE is +0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AMPH is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AMPH vs CRDL Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CRDL has a market cap of 217.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CRDL trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CRDL's P/E ratio is -7.51. In terms of profitability, AMPH's ROE is +0.10%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AMPH is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AMPH vs SIGA Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SIGA has a market cap of 213M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SIGA trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SIGA's P/E ratio is 11.00. In terms of profitability, AMPH's ROE is +0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, AMPH is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SIGA's competition here
Journey Medical Corporation (NASDAQ: DERM)
AMPH vs DERM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, DERM has a market cap of 206.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while DERM trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas DERM's P/E ratio is -20.24. In terms of profitability, AMPH's ROE is +0.10%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AMPH is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AMPH vs REPH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas REPH's P/E ratio is -8.04. In terms of profitability, AMPH's ROE is +0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AMPH is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check REPH's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AMPH vs LFCR Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, LFCR has a market cap of 169.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while LFCR trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas LFCR's P/E ratio is -4.22. In terms of profitability, AMPH's ROE is +0.10%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, AMPH is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LFCR's competition here
Organigram Global Inc. (NASDAQ: OGI)
AMPH vs OGI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, OGI has a market cap of 168.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while OGI trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas OGI's P/E ratio is -4.62. In terms of profitability, AMPH's ROE is +0.10%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AMPH is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check OGI's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AMPH vs THTX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas THTX's P/E ratio is -28.83. In terms of profitability, AMPH's ROE is +0.10%, compared to THTX's ROE of +0.17%. Regarding short-term risk, AMPH is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AMPH vs ASRT Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AMPH's ROE is +0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AMPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AMPH vs SCTL Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AMPH's ROE is +0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AMPH is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AMPH vs CPIX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CPIX has a market cap of 112.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CPIX trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CPIX's P/E ratio is -18.75. In terms of profitability, AMPH's ROE is +0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AMPH is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
AMPH vs PROC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PROC's P/E ratio is 1.53. In terms of profitability, AMPH's ROE is +0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AMPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PROC's competition here
BGM Group Ltd. (NASDAQ: BGM)
AMPH vs BGM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, BGM has a market cap of 100.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while BGM trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas BGM's P/E ratio is -0.91. In terms of profitability, AMPH's ROE is +0.10%, compared to BGM's ROE of -0.07%. Regarding short-term risk, AMPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BGM's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AMPH vs OPTN Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AMPH's ROE is +0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AMPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AMPH vs ZOM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AMPH's ROE is +0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, AMPH is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AMPH vs ZYBT Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ZYBT trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, AMPH's ROE is +0.10%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, AMPH is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
AMPH vs GRVI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AMPH's ROE is +0.10%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, AMPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AMPH vs ZYNE Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AMPH's ROE is +0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AMPH is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AMPH vs SSIC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AMPH's ROE is +0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AMPH is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
AMPH vs TLPH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TLPH trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TLPH's P/E ratio is -3.84. In terms of profitability, AMPH's ROE is +0.10%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AMPH vs VLNS Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AMPH's ROE is +0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, AMPH is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
AMPH vs DRRX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AMPH's ROE is +0.10%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, AMPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
AMPH vs INCR Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, INCR has a market cap of 51.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while INCR trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas INCR's P/E ratio is -2.01. In terms of profitability, AMPH's ROE is +0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AMPH is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AMPH vs JUPW Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AMPH's ROE is +0.10%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AMPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AMPH vs CPHI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CPHI has a market cap of 42.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CPHI trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CPHI's P/E ratio is -1.64. In terms of profitability, AMPH's ROE is +0.10%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AMPH is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AMPH vs QLI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas QLI's P/E ratio is -4.92. In terms of profitability, AMPH's ROE is +0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AMPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
AMPH vs HEXO Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AMPH's ROE is +0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AMPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AMPH vs RMTI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, RMTI has a market cap of 30.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while RMTI trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas RMTI's P/E ratio is -5.70. In terms of profitability, AMPH's ROE is +0.10%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AMPH is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AMPH vs AYTU Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas AYTU's P/E ratio is -1.19. In terms of profitability, AMPH's ROE is +0.10%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, AMPH is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AMPH vs CYTH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AMPH's ROE is +0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AMPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CYTH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AMPH vs TXMD Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, TXMD has a market cap of 23.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas TXMD's P/E ratio is 103.41. In terms of profitability, AMPH's ROE is +0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AMPH is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TXMD's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AMPH vs EVOK Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AMPH's ROE is +0.10%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, AMPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
AMPH vs BFRIW Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, AMPH's ROE is +0.10%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, AMPH is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AMPH vs OPTH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, OPTH has a market cap of 15.7M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while OPTH trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas OPTH's P/E ratio is -17.86. In terms of profitability, AMPH's ROE is +0.10%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AMPH is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AMPH vs ACRX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AMPH's ROE is +0.10%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
AMPH vs COSM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas COSM's P/E ratio is -0.29. In terms of profitability, AMPH's ROE is +0.10%, compared to COSM's ROE of -1.19%. Regarding short-term risk, AMPH is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AMPH vs AGRX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AMPH's ROE is +0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AMPH is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AMPH vs NLTX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AMPH's ROE is +0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AMPH is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AMPH vs LCI Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas LCI's P/E ratio is -0.04. In terms of profitability, AMPH's ROE is +0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AMPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AMPH vs ADMP Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AMPH's ROE is +0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AMPH is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
AMPH vs YCBD Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while YCBD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas YCBD's P/E ratio is -1.24. In terms of profitability, AMPH's ROE is +0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AMPH is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AMPH vs GELS Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while GELS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas GELS's P/E ratio is -1.11. In terms of profitability, AMPH's ROE is +0.10%, compared to GELS's ROE of -0.25%. Regarding short-term risk, AMPH is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
AMPH vs MNK Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas MNK's P/E ratio is -0.44. In terms of profitability, AMPH's ROE is +0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, AMPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AMPH vs FLGC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AMPH's ROE is +0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AMPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
AMPH vs UPC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, UPC has a market cap of 3.4M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while UPC trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas UPC's P/E ratio is -0.67. In terms of profitability, AMPH's ROE is +0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, AMPH is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
AMPH vs SBFM Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SBFM has a market cap of 2.8M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SBFM's P/E ratio is -0.19. In terms of profitability, AMPH's ROE is +0.10%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, AMPH is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AMPH vs PLXP Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AMPH's ROE is +0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AMPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
AMPH vs ATNX Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AMPH's ROE is +0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AMPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AMPH vs SNOA Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SNOA's P/E ratio is -1.14. In terms of profitability, AMPH's ROE is +0.10%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, AMPH is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AMPH vs SHPH Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SHPH has a market cap of 2.2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SHPH trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SHPH's P/E ratio is -0.17. In terms of profitability, AMPH's ROE is +0.10%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, AMPH is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SHPH's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
AMPH vs RDHL Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, RDHL has a market cap of 2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas RDHL's P/E ratio is 0.13. In terms of profitability, AMPH's ROE is +0.10%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, AMPH is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check RDHL's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
AMPH vs PROCW Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas PROCW's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.10%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, AMPH is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PROCW's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
AMPH vs SXTC Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, SXTC has a market cap of 1.9M. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while SXTC trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas SXTC's P/E ratio is 1.30. In terms of profitability, AMPH's ROE is +0.10%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, AMPH is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
AMPH vs YCBD-PA Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, AMPH's ROE is +0.10%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, AMPH is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
AMPH vs CYTHW Comparison August 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 955.9M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, AMPH is priced at $21.81 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 7.40, whereas CYTHW's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.10%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, AMPH is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CYTHW's competition here